UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 |
|
| ||||||||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | SEC 1473 (7-02) | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1. Title of Derivative Security (Instr. 4) |
2. Date Exercisable and Expiration Date (Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) |
4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) |
6. Nature of Indirect Beneficial Ownership (Instr. 5) |
||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
Aisling Capital II LP 888 SEVENTH AVE 30TH FL NEW YORK, NY 10106 |
 |  X |  |  |
AISLING CAPITAL PARTNERS LLC 888 SEVENTH AVENUE 30TH FLOOR NEW YORK, NY 10106 |
 |  X |  |  |
AISLING CAPITAL PARTNERS, LP 888 SEVENTH AVENUE 30TH FLOOR NEW YORK, NY 10106 |
 |  X |  |  |
SCHIFF ANDREW N 888 SEVENTH AVENUE 30TH FLOOR NEW YORK, NY 10106 |
 |  X |  |  |
Purcell Dennis J 888 SEVENTH AVENUE 30TH FLOOR NEW YORK, NY 10106 |
 |  X |  |  |
/s/ Lloyd Appel | 02/16/2012 | |
**Signature of Reporting Person | Date | |
/s/ Lloyd Appel | 02/16/2012 | |
**Signature of Reporting Person | Date | |
/s/ Lloyd Appel | 02/16/2012 | |
**Signature of Reporting Person | Date | |
/s/ Andrew N. Schiff | 02/16/2012 | |
**Signature of Reporting Person | Date | |
/s/ Dennis J. Purcell | 02/16/2012 | |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | On February 13, 2012, the issuer's wholly-owned subsidiary merged with ADMA Biologics, Inc., a privately-held Delaware corporation ("Former ADMA"). The issuer changed its name to ADMA Biologics, Inc. In connection with the merger and pursuant to the terms of the merger agreement, holders of Former ADMA's common stock received shares of the issuer's common stock and holders of options to purchase Former ADMA's common stock received options to purchase the same number of the issuer's common stock at the same exercise price. Aisling Capital II, LP ("Aisling") acquired the issuer's securities in exchange for securities of Former ADMA. The issuer's shares of common stock are not currently listed on an exchange or quoted on the OTC Bulletin Board. |
(2) | The reportable securities are owned directly by Aisling, and held indirectly by Aisling Capital Partners, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners, LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Mr. Elms has reported his holdings separately. |